


RareCyte® Circulating Tumor Cell analysis provided by NeoGenomics



Circulating Tumor Cells (CTCs) are implicated in the origin of cancer metastasis, which is responsible for around 90% of cancer-related mortalities. There is an association between the number of CTCs and the prognosis and response to therapy. Analysis of CTCs enables investigation of cancer cell biomarker expression and mutational status from a venous blood draw.

NeoGenomics' new and exciting RareCyte CTC service offering further galvanizes our comprehensive liquid and tissue biopsy modalities with a unique deployment providing exceptional sensitivity, accuracy and reproducibility, along with an end-to-end workflow from blood collection to single-cell isolation.


How does it work?



With this new service, NeoGenomics can offer:

- CTC enumeration and characterization through a reproducible end-to-end workflow, designed with consistency in mind to help drive translational and large clinical research studies.
- 5-day blood sample stability and up to four-year bank-before-stain option offers practical clinical sample shipping, staining and analysis pipelines.
- Up to six-channel fluorescence imaging with machine-learning enabled CTC detection.
- Support assay transfer, custom assay design, CTC panel verification and validation.
- Ability to add on safe and convenient single cell isolation for nucleic acid analysis.
- Compatibility with multiplexed immunofluorescence workflows and machine learning (ML) analytic pipelines.

RareCyte CTC images generated by NeoGenomics



NeoGenomics is a premier partner for Circulating Tumor Cell (CTC) analysis. The RareCyte CyteFinder® platform is a next-generation, non-invasive investigation into the cancer biology of patients, enabling circulating tumor cell enumeration and biomarker expression over time for clinical research. This highly sensitive, comprehensive technology is critical to developing treatment pathways that are rooted in precision medicine.

NeoGenomics is committed to our vision of uncompromising quality, exceptional service, and innovative solutions, serving the cancer community with a suite of targeted diagnostics that help oncologists and pathologists guide patients along their complex journeys. **For more information, please contact our Client Services team at 1.866.776.5907 option 3, or visit neogenomics.com**

For other services provided by NeoGenomics Pharma services that are complementary to the RareCyte CTC assay, please see neogenomics.com/pharma-services/lab-services.

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing, partnership opportunities and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry and immunohistochemistry through our worldwide network of CAP-accredited, CLIA-certified laboratories.

9490 NeoGenomics Way
Fort Myers, FL 33912
United States
Phone: 866.776.5907
Fax: 239.690.4237

7256 S. Sam Houston Pkwy W. Suite 300
Houston, TX 77085
United States
Phone: 800.720.4363/713.528.4363
Fax: 713.668.3565

A-One Business Center
Bâtiment A5, 2nd Floor
Z.A. La Pièce/Route de l'Etraz 1
1180 Rolle, Switzerland
Phone: +41 (0)21 721 06 00
Fax: +41 (0)21 826 00 73

NeoGenomics Singapore Pte Ltd
61 Science Park Road, #02-11,
Singapore 117525
Phone: +65 6591 5200

31 Columbia
Aliso Viejo, CA 92656
United States
Phone: 800.720.4363
Fax: 949.425.5865

NeoGenomics Laboratories, Inc.
4570 Executive Drive, Suite 250
San Diego, CA 92121
Phone: 949.445.7300 5056
Fax: 713.668.3565

Suzhou NeoGenomics
Pharmaceutical Research Co., Ltd
Building 6, Block 19, Yong'An Road
Huguan Industrial Park,
Suzhou New District, China



neogenomics.com

© 2022 NeoGenomics Laboratories, Inc. All rights reserved. All trademarks are the property of their respective owners. Rev. 062022